Results 251 to 260 of about 35,569 (305)

Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose co‐transporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have separately shown renoprotective effects in clinical trials in people with type 2 diabetes. It is unclear whether combining these agents produces incremental kidney outcome benefits. Materials and Methods Retrospective cohort
William Hinton, Mark Joy, Anna K. Forbes, Martin B. Whyte, José M. Ordóñez‐Mena, Xuejuan Fan, Filipa Ferreira, Bernardo Meza‐Torres, Neil Munro, Simon de Lusignan, David C. Wheeler, Michael D. Feher   +11 more
wiley   +1 more source

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Albuminuria Irrespective of Baseline HbA1c Levels: A Participant‐Level Exploratory Analysis of the Randomised CONFIDENCE Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This prespecified analysis evaluated whether the safety and efficacy of finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i) combination vary by baseline glycated haemoglobin (HbA1c). Materials and Methods Adults with type 2 diabetes and a urinary albumin‐to‐creatinine ratio (UACR) of 100 − < 5000 mg/g, estimated glomerular ...
Janet B. McGill, Jennifer B. Green, Hiddo J. L. Heerspink, Johannes F. E. Mann, Amy K. Mottl, Julio Rosenstock, Peter Rossing, Muthiah Vaduganathan, Masaomi Nangaku, Meike Brinker, Charlie Scott, Katja Rohwedder, Li Li, Na Li, Margarida Seco, Rajiv Agarwal   +15 more
wiley   +1 more source

Molecular Characterization of the Effect of Glucagon-Like Peptide-1 Receptor Agonist Semaglutide in the Nephrotoxic Serum Nephritis Mouse Model. [PDF]

Kidney360
Martinez JM, Ougaard M, Grancharova T, Zdravkovic RD, Østergaard MV, Bénardeau A, Knudsen LB, Pyke C, Kvist PH, Hvid H.   +9 more
europepmc   +1 more source

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. [PDF]

Diabetologia
Maier GA, Rathmann W, Kuß O.
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonist use and clinical outcomes after posterior cervical spinal fusion for degenerative pathologies: A large cohort retrospective analysis. [PDF]

N Am Spine Soc J
Rajkovic C, Jain A, Shafi M, Omobhude O, Azad T, Carpenter A, Witham TF, Kinon MD, Wainwright JV.   +8 more
europepmc   +1 more source

Semaglutide in Adolescents Living With Obesity: A Real‐World Data Study Exploring Predictors of Treatment Response

Diabetes, Obesity and Metabolism, EarlyView.
Valeria Cimador, Sophie Robertson, Christine Desmond, Jessica Dodgson, Elizabeth van Boxel, Nikki L. Davis, Rebecca J. Moon   +6 more
wiley   +1 more source

Patients on Long-Term Preoperative Glucagon-Like Peptide-1 Receptor Agonist Therapy Show Significant Reductions in Postoperative Complications After Elective Laminectomy in Overweight Adults: A Propensity-Matched Study. [PDF]

Int J Spine Surg
Wahid M, Zaidi Z, Isa S, Alshaikhsalama Y, Aoun SG.   +4 more
europepmc   +1 more source

Methodological and statistical errors distort the effects of glucagon-like peptide-1 receptor agonist drugs on body composition in patients with type 2 diabetes mellitus. [PDF]

Diabetol Metab Syndr
Trexler ET.
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication.

JAMA Health Forum
Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD.   +5 more
europepmc   +1 more source